Skip to content
MARKETS / BALCAO / BDPT
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Bioadaptives, Inc. BDPT

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$18,278
▲ 44.3% YoY
$-1.6M
$-534,025
In brief

What this company does

BioAdaptives' core business is to investigate, market, and distribute natural plant, algal, and cyanobacteria-based products and medical devices that enhance health and wellness for humans and animals, with a focus on nootropics, anti-aging, weight control, relaxation, pain relief, and anti-viral benefits. Effective November 15, 2021, the Company entered into a marketing agreement for an FDA-cleared Class Tl medical device, the Lung Flute™. The Company's current products in development include dietary supplements utilizing natural ingredients and proprietary methods to optimize the availability of nutrients in foods and beverages. We operate as a Research and Development nutraceutical company. Currently, the Company has one full-time executive employee.

Written from the business description in BioAdaptives, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 April 2026. Every sentence was checked against that document before publication.

Growth
USD 18,278.00
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.6
-0.8M2014201520182019202020212022202320242025
Compound annual growth
+2.1%
+2.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.3% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−8523 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -5701.8% · Net -8523.4%
-5000%2014201520182019202020212022202320242025
ROE

Not applicable: equity was negative in this period, so return on equity has no meaning.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $
FY2025 · FCF -534025.0
-200000-4000002014201520182019202020212022202320242025

Total assetsUSD 225,901.00
EquityUSD -2.1M
CashUSD 215,205.00
Gross debtUSD 32,096.00
Net debtUSD -183,109.00
Current ratio0.09×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820152014
Revenue $B0.00.00.00.00.00.00.0···
Operating income $B−0.0−0.0−0.0−0.0·−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0······−0.0−0.0
Income tax $B0.00.0·0.00.00.00.0···
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0·······−0.0
EPS, diluted $−0.15−0.11···−0.04−0.01−0.08−0.02−0.21
Dividend / sh $··········
Payout %··········
ROE %··········
Shares out B0.010.000.010.250.050.020.020.020.010.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 45 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 50 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2014

Share this section

Download image